Clinical Trial Update: Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating GW5282 in combination with Golidocitinib (BEI-DOU3) for T-cell lymphoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• GW5282 (GW5282)
• Golidocitinib (golidocitinib)

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: T-cell Lymphomas | Phase 1, Phase 2 | Status: RECRUITING